



Contact:

David Waldman or Natalya Rudman
Crescendo Communications Europe S.A.
Email: mmd@crescendo-ir.com

Dom Maklerski WDM S.A.
Email: us@wdmcapital.com
Tel: (+48 71) 79 11 555

Milestone Medical Inc. Receives CE Mark Approval for Intra-Articular Instrument

LIVINGSTON, NJ, September 15, 2014 -- Milestone Medical Inc. (WAR: MMD), today announced it has received CE Mark regulatory approval to market and sell its intra-articular instrument in Europe.

Leonard Osser, Chief Executive Officer of Milestone Medical stated, "CE approval for our intra-articular instrument follows the recent CE approval of our epidural instrument. Regulatory approval in Europe for both of these instruments is validation of our technology and allows us to move forward with our plans to commercialization the technology in Europe. We are now in the process of evaluating potential strategic partners to distribute our intra-articular instrument in Europe. We believe we are well positioned to enter this multi-billion dollar market since conventional injections are painful, a problem eliminated with our instrument, and not always efficacious, as doctors often fail to locate the intra-articular space or use inappropriate volumes of hyaluronic acid."

Milestone's injection technology is based on a patented Dynamic Pressure Sensing® system (DPS®), intended to measure the density of body tissue and thus help a clinician know the location of a hypodermic needle during an injection. The system utilizes computer controlled technology to provide real-time feedback to the medical practitioner and identify with precision when a needle has reached the location where a drug should be administered to a patient. It has the added advantage in other applications of controlling the pain that patients typically associate with injections.

About Milestone Medical Inc.

Milestone Medical, Inc. has developed epidural and intra-articular drug delivery systems based on a patented, painless, computer-controlled injection and drug delivery technology originally developed by Milestone Scientific, Inc. Development of both the epidural and intra-articular instruments is now complete and the Company is currently pursuing regulatory approval for both instruments in the U.S. and European Union. For more information please visit www.medicalmilestone.com.

Safe Harbor Statement

This press release contains forward-looking statements regarding the timing and financial impact of Milestone's ability to implement its business plan, expected revenues and future success. These statements involve a number of risks and uncertainties and are based on assumptions involving judgments with respect to future economic, competitive and market conditions and future business decisions, all of which are difficult or impossible to predict accurately and many of which are beyond Milestone's control. Some of the important factors that could cause actual results to differ materially from those indicated by the forward-looking statements are general economic conditions, failure to achieve expected revenue growth, changes in our operating expenses, adverse patent rulings, FDA or legal developments, competitive pressures, changes in customer and market requirements and standards, and the risk factors detailed from time to time in Milestone's periodic filings with the Securities and Exchange Commission. The forward looking-statements in this press release are based upon management's reasonable belief as of the date hereof. Milestone undertakes no obligation to revise or update publicly any forward-looking statements for any reason.